Podcasts about Mesothelioma

Clarence Ford spoke to Professor David Kinley on his new book: In a Rain of Dust: Death, Deceit and the effects of South Africa’s asbestos mining legacy. Views and News with Clarence Ford is the mid-morning show on CapeTalk. This 3-hour long programme shares and reflects a broad array of perspectives. It is inspirational, passionate and positive. Host Clarence Ford’s gentle curiosity and dapper demeanour leave listeners feeling motivated and empowered. Known for his love of jazz and golf, Clarrie covers a range of themes including relationships, heritage and philosophy. Popular segments include Barbs’ Wire at 9:30am (Mon-Thurs) and The Naked Scientist at 9:30 on Fridays. Thank you for listening to a podcast from Views & News with Clarence Ford Listen live on Primedia+ weekdays between 09:00 and 12:00 (SA Time) to Views and News with Clarence Ford broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/erjiQj2 or find all the catch-up podcasts here https://buff.ly/BdpaXRn Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

where the skies are so blue Checkout MyBookie for the best and most awesome LIVE CASINO https://www.mybookie.ag/Support the show

Sandra M. Oliver-McNeil, DNP, ACNP-BC, FACC, JACC: Case Reports Associate Editor, is joined by author Victor A. Ferrari, MD, FACC discussing this study from Ravindra et al presented at ACC.25 and published in JACC: Case Reports. This clinical vignette highlights the case of a 62-year-old male who presented with worsening dyspnea and was ultimately found to have constrictive pericarditis secondary to primary pericardial mesothelioma. The use of multimodality imaging can facilitate early diagnosis of this rare condition, helping to initiate treatment options for an otherwise high-mortality disease.

Send us a text

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion of two of the most challenging thoracic malignancies – NUT carcinoma and mesothelioma. Listen to the episode to learn about the role of next-generation sequencing in diagnosis and treatment selection, as well as current and future targeted therapy in the management of both. Guests Melina Marmarelis, MD MSCE Assistant Professor Medical Director, UPenn Mesothelioma University of Pennsylvania Jia Luo, MD Medical Oncologist, Thoracic Oncology Program, Dana-Farber Cancer Institute Faculty, Brigham and Women's Hospital and Harvard Medical School

EP263*IF YOU ARE LISTENING TO THIS AUDIO PORTION ON YOUTUBE, SWITCH OVER TO THE VIDEOJohn Vasos first two appearances below:➡️ EP116: https://youtu.be/YPji5Yu8UCQ?si=ni0Ny4jMFoG-q846➡️ EP219: https://youtu.be/inBQ0Z_Xjy4?si=6HgN2Dw2l1uy8TE5This John Vasos conversation was recorded in April of 2024. Guest Jake Cole was added for this episode to revisit his role on bringing John Vasos essentially to Hard Parking. On February 11, 2025, John Vasos lost his battle with Mesothelioma at the age of 68 after losing his long battle with Mesothelioma. This is his 3rd time on Hard Parking but this episode was never meant to be a podcast, but instead a recorded collection of valuable Acura NSX information from the heart and mind of one of America's Mount Rushmore of Acura NSX minds. Many thanks to content contributors of this video:Mary E BushPeter CunninghamJake ColeMatt ColeLeon SchmidtBryan HunterDr. Ajay SharmakeN SaXChris WillsonEmma MikolicJohn is survived by his son, daughter, and brother.Contact Hard Parking with Jhae Pfenning:email: HardParkingPodcast@gmail.comWebsite: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.Hardparkingpod.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.patreon.com/hardparkingpodcast/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/hardparkingpod/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/@HardParking ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Send us a text

Send us a text

Dr. Hedy Kindler joins us on the podcast to discuss the latest update to the treatment of pleural mesothelioma guideline. She discusses the latest changes to the updated recommendations across topics including surgery, immunotherapy, chemotherapy, pathology, and germline testing. Dr. Kindler describes the impact of this guideline and the need for ongoing research in the field. Read the full guideline update, “Treatment of Pleural Mesothelioma: ASCO Guideline Update” at www.asco.org/thoracic-cancer-guidelines.   TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02425 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Hedy Kindler from the University of Chicago, lead author on “Treatment of Pleural Mesothelioma: ASCO Guideline Update.” Thank you for being here today, Dr. Kindler. Dr. Hedy Kindler: Thank you so much. Brittany Harvey: Then, before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines in ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Kindler, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to jump into the content of this podcast episode, first, Dr. Kindler, can you provide an overview of the purpose and scope of this guideline update on pleural mesothelioma? Dr. Hedy Kindler: The initial ASCO practice guideline on mesothelioma, which we published in 2018, was quite comprehensive, but since that time incredible progress has been made which has truly transformed the management of this disease. So we felt it was really important to update the guideline now, focusing on four key areas: the role of surgery, new systemic treatments, pathologic insights, and germline testing. Brittany Harvey: Great. Thank you for highlighting those key areas of the guideline. And so I'd like to next review the key updated recommendations for our listeners. So starting with what are the new updates for surgery? Dr. Hedy Kindler: So surgery has always been controversial in meso, with significant geographic variation in its use. Now, it's even more controversial. Recent randomized data from the MARS 2 trial, placed in the context of other data we also reviewed in this update, suggest that surgical cytoreduction should not be routinely offered to all patients based solely on anatomic resectability. Surgery should only be offered to highly selected patients with favorable prognostic characteristics. This includes comprehensively staged patients with early-stage epithelioid tumors. Patients should preferably be treated at centers of excellence which have documented low morbidity and mortality, and this should also be done in the context of multimodality therapy and preferably within clinical trials. Brittany Harvey: Understood. I appreciate you reviewing those recommendations for who surgery should be offered to. So following those, what are the main recommendations for immunotherapy for treating pleural mesothelioma? Dr. Hedy Kindler: So for a disease in which for 16 years there was only one FDA-approved regimen, pemetrexed and platinum, the pace of recent changes in systemic therapy has been a welcome change with the FDA approval of doublet immunotherapy in October of 2020 and the approval of chemo immunotherapy just a few months ago in September of 2024. Now that we have choices, we've tried to help clinicians determine the optimal treatment regimen for the individual patient. Doublet immunotherapy with ipilimumab and nivolumab should be offered as a first-line systemic option to any mesothelioma patient. For patients with non-epithelioid histology, doublet immunotherapy is hands down the recommended regimen based on the dramatic improvement in survival from 8.8 to 18.1 months for immunotherapy compared with chemo. For patients with previously untreated epithelioid mesothelioma, either ipilimumab-nivolumab immunotherapy or platinum-pemetrexed chemotherapy are reasonable options. Therapy can be individualized based on the patient's comorbidities, acceptance of differing toxicities. and treatment goals. Chemoimmunotherapy with pembrolizumab, pemetrexed, and carboplatin is a newer treatment option for patients with newly diagnosed pleural mesothelioma. This regimen is noteworthy for its very high objective response rate of 62%. Brittany Harvey: It's great to have those new options to improve outcomes for patients. Beyond the chemoimmunotherapy recommendation that you just described, what are the highlights for chemotherapy recommendations? Dr. Hedy Kindler: So pemetrexed platinum-based chemotherapy with or without bevacizumab still plays a role in this disease and should be offered as a first-line treatment option in patients with epithelioid histology. This regimen is not recommended in patients with non-epithelioid disease unless they have medical contraindications to immunotherapy. Pemetrexed maintenance chemotherapy following pemetrexed-platinum chemotherapy is not recommended. Brittany Harvey: Thank you for reviewing those recommendations as well. So then next, what are the important changes regarding pathology? Dr. Hedy Kindler: Well, one fun fact is that we've changed the name of the disease. It's no longer malignant mesothelioma. Now it's just mesothelioma. Since the non-malignant mesothelial entities have been renamed, all mesos are now considered malignant, so there's no need to use the prefix malignant in the disease name. Mesothelioma should be reported as epithelioid, sarcomatoid, or biphasic because these subtypes have a clear prognostic and predictive value. Knowing the subtype helps us decide on whether chemotherapy or immunotherapy is the optimal treatment for a patient, so it must be reported. Additionally, within the epithelioid subtype, histologic features, including nuclear grade, some cytologic features, and architectural patterns should be reported by pathology because they have prognostic significance. Pathologists have recently identified a premalignant entity, mesothelioma in situ, which can be found in patients with long standing pleural effusions and should be considered in the differential diagnosis. In the appropriate clinical setting, additional testing, including BAP1 and MTAP IHC should be performed. Brittany Harvey: Definitely. These pathologic recommendations are important for treatment selection. So in that same vein, in the final section of the recommendations, what are the updated recommendations from the panel regarding germline testing? Dr. Hedy Kindler: This is one of our most important recommendations, that universal germline testing should be offered to all mesothelioma patients. The proportion of patients with mesothelioma who have pathogenic or likely pathogenic germline variants is similar to other diseases in which universal germline genetic testing and counseling are now the standard of care. This is most commonly observed in the tumor suppressor gene BAP1 and this not only affects cancer risk in patients and their family members, but also has key prognostic significance. For example, pleural mesothelioma patients with BAP1 germline mutations who receive platinum-based chemotherapy live significantly longer, 7.9 years compared to 2.4 years for those without these mutations. Thus, we recommend that all patients with mesothelioma should be offered universal germline genetic counseling and/or germline testing. Brittany Harvey: So there were a large amount of new and updated recommendations in this update. So in your view Dr. Kindler, what is the both importance of this update and how will it impact both clinicians and patients with pleural mesothelioma? Dr. Hedy Kindler: Even as we were researching and writing this update, new data kept emerging which we needed to include. So it's clearly a time of great progress in the management of this disease. We've comprehensively reviewed and analyzed the extensive emerging data and provided clinicians with a roadmap for how to incorporate these new advances into their management of this disease. Brittany Harvey: Absolutely, that is key for optimal patient care. So you've just mentioned emerging data and rapid evidence generation, so what future research developments are being monitored for changes in the treatment of pleural mesothelioma? Dr. Hedy Kindler: Despite these recent advances in disease management, mesothelioma continues to be a lethal cancer, and there's clearly a need to develop better treatments. This includes ongoing studies of novel immunotherapeutic agents such as bispecific antibodies, cell therapy using chimeric antigen receptors targeting mesothelioma tumor antigens, and precision medicine approaches to target tumor suppressor genes. Finally, strategies for early cancer detection and prevention are vital for individuals predisposed to develop mesothelioma due to BAP1 and other germline mutations, as well as for those who are occupationally or environmentally exposed to asbestos. Brittany Harvey: Absolutely. We'll look forward to these new updates to continue development in the field. So thank you so much for this mountain of work to update this guideline, and thank you for your time today, Dr. Kindler. Dr. Hedy Kindler: Thank you so much. It's been a pleasure. Thank you for asking me to do this. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline update, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Greetings, dear listener, and welcome back to "Jump on the Bat-Wagon" with James and Brian, where we watch through the entire DC Animated Universe from start to finish in the controversial airdate order, to experience these shows the way human beings experienced them in the far-gone days of the 1990s. The twist? Brian has never seen any of the DCAU. Will he become a super-fan like James or regret his decision? This week's episode: "Little Big Head Man" "Superman: The Animated Series" Original airdate: 11/21/1998 Mr. Mxyptlk gets into trouble with the rulers of his planet when he enlists Bizarro's help to create havoc on Earth. Timecodes: 0:00 - Intro 17:17 - Review and Ratings 59:25 - Yoppie Mail 1:23:05 - Outro Next episode: Bonus: The Yopisode Guide (Most of STAS and TNBA) DCAU Airdate Viewing Order: https://bit.ly/watchdcau Send us an email! batwagonpod @gmail Buy us a coffee! https://www.buymeacoffee.com/yoppie Buy a Yoppie Dude T-Shirt! https://watchtowerdatabase.com/shop New episodes debut Fridays on the Podtower YouTube channel and your favorite podcast feed! https://www.youtube.com/thepodtower Subscribe to the Watchtower Database for more DCAU videos! https://www.youtube.com/watchtowerdatabase Hang out with us on Discord! https://discord.com/invite/RWZ7TaxAar

Nicholas Vogelzang of Vogelzang Law joins Jon Hansen on Let's Get Legal to discuss why Illinois is important to asbestos litigation and why there are so many cases tried here. For more information, call (312) 466-1669.

Listen to a soundcast of the 9.17.2024 FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma.

This coming weekend, the Trail to Triumph team are running 250km's over three days to raise money for Heart of Australia and Mesothelioma.Some, (like me) are running 25km's during the same time.Elisha Parker caught up with me to share the vital role fundraising plays in finding a cure for this devastating disease.  To donate, head to trailtotriumph.com.au

The FDA clears capsule that creates sensation of fullness in the stomach; Complete Response Letter issued for gastroparesis treatment; Apple's sleep apnea notification feature gets clearance; Keytruda gains malignant pleural mesothelioma indication; Ebglyss approved for atopic dermatitis

In a special episode of Lung Cancer Considered, host Dr. Stephen Liu discuss the recent FDA approval of pembrolizumab plus platinum and pemetrexed for mesothelioma, based on the phase III KEYNOTE 483 study. Guest: Dr. Ibiayi Dagogo-Jack is a thoracic oncologist from Massachusetts General Hospital and Assistant Professor at Harvard Medical School Guest: Dr. Quincy Chu is a thoracic oncologist at the University of Alberta Cross Cancer Institute's New Drug Development Program and CCTG Investigational New Drug Committee Chair

Over the course of the last couple of years, I, like you, have seen countless television commercials for law firms inviting viewers to engage in lawsuits for a variety of causes, many times because of exposure to contaminants at Camp LeJeune, or for illnesses like Mesothelioma. I've often times turned to my wife to tell her that we are not far from seeing the same kinds of ads pop up for those who were encouraged and perhaps forced into gender transitioning steps by parents, medical doctors, educators, and others. The reality is that several suits are now in progress, and there are law firms working to announce their willingness to represent detransitioners who want to sue those who lied about the dangers of these medical interventions. Parents, this reminds us of our need to not only advocate for our kids with sensibility, but to do so from a biblical perspective. At creation, God made two genders, and he has created all people to live into the gender that was given at conception.

Michelle T. Pawlowski, Litigation Associate Attorney at Vogelzang Law, joins Jon Hansen on Let’s Get Legal! Michelle and Jon talk about the development of Mesothelioma, the investigation of cases, and what clients should look for in an attorney. How Michael Madigan’s case will be affected by the overturning of the bribery conviction of former Indiana […]

BUFFALO, NY- July 15, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.” Malignant pleural mesothelioma (MPM) is an aggressive neoplasm and affected patients have low survival rates. In this new retrospective study, researchers Kazuhiro Kitajima, Kozo Kuribayashi, Toshiyuki Minami, Hiroyuki Yokoyama, Akifumi Nakamura, Masaki Hashimoto, Takashi Kijima, Seiki Hasegawa, Hayato Kaida, and Koichiro Yamakado from Hyogo Medical University and Kindai University Faculty of Medicine examined the effectiveness of fluorodeoxyglucose positron emission tomography (FDG-PET) criteria, i.e., immunotherapy-modified PET response criteria in solid tumors (imPERCIST), with morphological computed tomography (CT) criteria, i.e., modified response evaluation criteria in solid tumors (mRECIST), to evaluate patients with unresectable MPM undergoing nivolumab plus ipilimumab combination therapy as first-line treatment regarding response and prognosis prediction. “Results for malignant pleural mesothelioma (MPM) patients following first-line treatment with nivolumab plus ipilimumab obtained with immunotherapy-modified PERCIST (imPERCIST), shown by [18F] (FDG-PET/CT), and modified RECIST (mRECIST), shown by CT, were compared for response evaluation and prognosis prediction.” Twenty-six patients (23 males, 3 females; median 73.5 years) with histologically proven MPM and no curative surgery received nivolumab plus ipilimumab combination therapy. FDG-PET/CT and diagnostic CT scanning at the baseline, and after 2–4 cycles (2 in three, 3 in 17, 4 in six patients) were performed. Therapeutic response findings evaluated using imPERCIST and mRECIST were compared. PFS and OS analyses were done using log-rank and Cox methods. Results: imPERCIST indicated nine progressive metabolic disease (PMD), eight stable metabolic disease (SMD), four partial metabolic response (PMR), and five complete metabolic response (CMR) cases. mRECIST showed nine with progressive disease (PD), nine stable disease (SD), seven partial response (PR), and one complete response (CR). Although high concordance was noted (κ = 0.827), imPERCIST correctly judged a greater percentage with CMR (15.4%). Following a median 10.0 months, 15 patients showed progression and eight died from MPM. With both, progression-free survival (PFS) and overall survival (OS) were significantly longer in patients without progression (CMR/PMR/SMD, CR/PR/SD, respectively) as compared to PMD/PD patients (imPERCIST p < 0.0001 and p = 0.015, respectively; mRECIST p < 0.0001 and p = 0.015, respectively). “For unresectable MPM patient examinations, FDG-PET and CT provide accurate findings for evaluating tumor response and also prognosis prediction following first-line nivolumab plus ipilimumab immunotherapy (approximately three cycles).” DOI - https://doi.org/10.18632/oncotarget.28594 Correspondence to - Kazuhiro Kitajima - kazu10041976@yahoo.co.jp Video short - https://www.youtube.com/watch?v=7ZRTRwig60Y About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM

Mesothelioma, lung cancer from asbestos exposure, asbestosis, and other personal injury cases, are the cases that Vogelzang Law is helping people with. Nicholas Vogelzang of Vogelzang Law joins Jon Hansen on Let’s Get Legal to discuss how he started the law firm and the types of cases he’s seen. Mesothelioma is a cancer of the […]

ASCO 2024 beat many attendees' expectations with interesting and thought-provoking lung cancer and mesothelioma studies. While not all of these will change the face of patient treatment, they will add to a body of evidence for biomarkers and build on the blocks of tailoring treatment to patients.Links to studies discussed in this episode (subscription may be required):BEAT-meso: Link Checkmate 816 4 year update: LinkMIST5: LinkctDNA-Lung-DETECT: Link BEAT-SC: Link For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Professor Eric Lim discusses the outcomes after extended pleurectomy decortication plus chemotherapy versus chemotherapy alone for pleural mesothelioma.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this episode our team dives into the diagnosis, workup and management of malignant pleural mesothelioma. Listen as we debate the pros and cons of surgical management of this disease with extrapleural pneumonectomy versus pleural decortication and discuss the nuances of choosing the right approach for the right patient. Learning Objectives - Describe the workup and staging of a patient with malignant pleural mesothelioma - List the subtypes of malignant pleural mesothelioma, characteristics of resectable disease, and patient factors which impact surgical candidacy  - Describe the approach to an extrapleural pneumonectomy and pleural decortication - Analyze which surgical approach is best for various subsets of patients - Describe the adjuvant treatment for malignant pleural mesothelioma Hosts Kelly Daus MD, Adam Bograd MD, Peter White MD, Brian Louie MD Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out more recent episodes: https://app.behindtheknife.org/listen

On this episode of Speeding Bullitt: The Life and Films of Steve McQueen, I'm joined by Marshall Terrill, writer and Steve McQueen expert. Together, we explore McQueen's relationship with his third wife, Barbara Minty, his struggle with Mesothelioma, and his passing on November 7, 1980.

In the first episode of Glauc Talk, Will and Kristin sit down to talk about the Change Healthcare cyber attack and how it compared to the Anthem cyber attack of 2015, they have a little couple therapy moment where they tell each other something they are wrong about, and Will tries to remember a disease associated with the Mesothelium. — We want to hear YOUR stories (and medical puns)! Shoot us an email and say hi! knockknockhi@human-content.com Can't get enough of us? Shucks. You can support the show on Patreon for early episode access, exclusive bonus shows, livestream hangouts, and much more! – http://www.patreon.com/glaucomflecken  -- A friendly reminder from the G's and Tarsus: If you want to learn more about Demodex Blepharitis, making an appointment with your eye doctor for an eyelid exam can help you know for sure. Visit http://www.EyelidCheck.com for more information.  This episode is brought to you by pRxcision. To see a demo, Go to http://www.prxcision.com/kkh. Today's episode is brought to you by the Nuance Dragon Ambient Experience (DAX). It's like having a virtual Jonathan in your pocket. If you would like to learn more about DAX Copilot check out http://nuance.com/discoverDAX and ask your provider for the DAX Copilot experience. Produced by Human Content Learn more about your ad choices. Visit megaphone.fm/adchoices

In this Fellows Forum interview, Dr. Samuel Kareff speaks with Dr. Estela Rodriguez, Clinical Research Lead of the Thoracic Site Disease Group at the University of Miami Sylvester Comprehensive Cancer Center, about recent research advances in mesothelioma, the emerging roles of immunotherapy and biomarker testing, and the importance of ensuring access to care for patients with this rare disease.

Melina Marmarelis, MD, Thoracic Medical Oncologist, UPenn joins us for an interview about precision medicine. She discusses biomarker information, such as histology (currently most valuable), but also molecular testing such as NF2, MTAP, CDKN2A mutations that can be used when determining precision medicine treatments. Other topics discussed are BAP1 mutations, PDL1 expression, mutational burden, and oncolytic viruses. The interview is moderated by Julie White, BSN, OCN, RN who is the patient services director at the Mesothelioma Applied Research Foundation. More information is available at curemeso.org.

This week's episode will be focusing on Malignant Mesothelioma. We will go over the important details on diagnosis, work-up, the different subtypes, and staging as well as treatment options for operable and inoperable disease.

Host Tom Simmons is joined by our guests from the law firm Brown Rudnick LLP, Partner Kyle Johnson and Counsel Anthony J. Boccamazzo, as well as HRP's CEO Dan Titus, to discuss PFAS in the context of class action lawsuits. Perhaps you've been struck, like us, by the similarities between class action lawsuit advertising for PFAS related injuries and asbestos related mesothelioma. It got us interested in the history of similar class action lawsuits and what that could tell us about the future of PFAS litigation.Join us for a great conversation. Listen to learn more and subscribe to The Pulse for all the details. Listen to learn more and subscribe to The Pulse for all the details.

O se tala fiafia le ono maua i se taimi lata mai o se su'ega poo se test e vave iloa ai ma togafitia tagata e a'afia i le mesothelioma, o se kanesa e mafua mai i le manavaina o le pefu o le asbestos.

Michael Offin, MD, MSKCC, joins us for an informative session about chemotherapy drugs, their uses, side effects, and supportive medications.

James Hardie Industries' involvement in the asbestos industry significantly shaped its trajectory from the mid-20th century. By the 1930s, the company had begun producing asbestos-containing products, capitalizing on the material's fire-resistant and insulating properties. This move propelled James Hardie into a dominant position within the asbestos industry, with its products widely used in construction throughout Australia and globally. However, by the 1970s, concerns about asbestos-related health risks began to emerge, leading to a shift in public perception and regulatory scrutiny.Join Matthew and Holly as they work their way through the history of the company who has become synonymous with asbestos exposure, their deeds and missteps, court cases and extradition treaties.

James Hardie Industries' involvement in the asbestos industry significantly shaped its trajectory from the mid-20th century. By the 1930s, the company had begun producing asbestos-containing products, capitalizing on the material's fire-resistant and insulating properties. This move propelled James Hardie into a dominant position within the asbestos industry, with its products widely used in construction throughout Australia and globally. However, by the 1970s, concerns about asbestos-related health risks began to emerge, leading to a shift in public perception and regulatory scrutiny.Join Matthew and Holly as they work their way through the history of the company who has become synonymous with asbestos exposure, their deeds and missteps, court cases and extradition treaties.

Baryulgil mine, situated in north-east NSW, gained prominence for asbestos extraction during the mid-20th century. While it initially provided economic opportunities for the Baryulgil Indigenous community through employment, the mine's asbestos production later caused severe injury to said workers. Those workers faced asbestos-related diseases like mesothelioma and asbestosis, diseases that destroy the lung tissue and leave sufferers gasping for air.Over time, heightened awareness of asbestos dangers led to the mine's scrutiny and eventual closure. Join Holly & Matthew as they go through the worker safety debates and the environmental challenges offered by such an event, journeying into the complexities of a community caught between progress and peril.

Over the course of the last couple of years, I, like you, have seen countless television commercials for law firms inviting viewers to engage in lawsuits for a variety of causes, many times because of exposure to contaminants at Camp LeJeune, or for illnesses like Mesothelioma. I've often times turned to my wife to tell her that we are not far from seeing the same kinds of ads pop up for those who were encouraged and perhaps forced into gender transitioning steps by parents, medical doctors, educators, and others. The reality is that several suits are now in progress, and there are law firms working to announce their willingness to represent detransitioners who want to sue those who lied about the dangers of these medical interventions. Parents, this reminds us of our need to not only advocate for our kids with sensibility, but to do so from a biblical perspective. At creation, God made two genders, and he has created all people to live into the gender that was given at conception.

Medical oncologist Dr. Joshua Reuss, an expert in lung cancer, mesothelioma and thymoma, and pulmonologist Dr. Rebecca Krochmal, an expert in benign and malignant airway and pleural disease, both with MedStar Georgetown  University Hospital in Washington, D.C., address questions related to finding and treating lung cancer. For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Thank you to our Sponsor:  Quip - If you go to getquip.com/trashtuesday right now, you'll get 20% any Electric Toothbrush, Mint & Gum Dispenser, Water Flosser. Quip - the good habits company. FINALLY! Trash Tuesday Merch!! Get it at https://itstrashtuesday.com/   See Esther on tour. Check out dates at estheronice.com See Annie on tour. Check out dates at https://www.annielederman.com/shows   More Michael Blaustein: Instagram - https://www.instagram.com/blaucomedy/ Twitter - https://twitter.com/blaucomedy/ https://www.blaucomedy.com/ Stiff Socks Podcast - https://trevorwallacecomedy.com/stiff-socks 00:00 - Blaustein's upset there's not a pedicure 02:01 - Bluastein is here and dressed like a cow 08:03 - Rumors about Blaustein's member 10:30 - Blaustein taught many people how to kiss 13:00 - Korean Spa spy revealed 17:00 - Blaustein's foot criteria 23:45 - How old were you when you realized that you look at feet and get a boner 27:58 - Rating Khalyla's feet 32:10 - Thigh gaps 34:30 - Revisiting the boxer brief debate 40:20 - Stinky feet vs. clean feet 45:40 - Have you ever had really in-love sex 49:40 - Mesothelioma and hyper mobility 53:50 - Four hall passes a year 57:53 - Cuck fantasies 01:02:40 - Thrinder 01:04:30 - A couple's third   Subscribe! https://bit.ly/HitOurButtonsOfficial Clips Channel: https://bit.ly/2QDAi8X Trash Tuesday Podcast iTunes Audio Feed: https://bit.ly/TrashTuesdayPodTrash Tuesday Podcast Spotify Audio Feed: https://bit.ly/TTPodAudioTrash Tuesday Instagram: https://www.instagram.com/itstrashtuesday     Listen to our other Podcasts: TigerBelly - https://podcasts.apple.com/us/podcast/tigerbelly/id1041201977 Rick and Esther Have a Time - https://podcasts.apple.com/us/podcast/rick-and-esther-have-a-time/id1694264079 AnnieWood - https://podcasts.apple.com/us/podcast/anniewood/id1653515392   Follow Us: Khalyla Kuhn - https://www.instagram.com/khalamityk Annie Lederman - https://www.instagram.com/annielederman Esther Povitsky - https://www.instagram.com/esthermonster Theme Song Written by: Bobby Lee http://instagram.com/bobbyleelive Banana Break Song by: Can Nguyen 

Mesothelioma is a particularly challenging cancer to treat and there had been relatively few updates in its management until the recent integration of immunotherapy into treatment guidelines. To discuss current strategies to treat Mesothelioma, Dr. Stephen Liu leads an informed discussion with two international Mesothelioma experts.

A long-awaited antitrust case against Amazon's massive online retail operations is expected to be filed in federal court as soon as Tuesday, according to three people with knowledge of the matter. The Federal Trade Commission has been preparing a complaint since at least the start of this year targeting an array of Amazon's business practices. Also, is SCOTUS going after abortion pills? In a case that takes up the availability of widely used abortion pill mifepristone, justices could decide whether a single court can limit abortion access in states that protect it, as well as roll back Food and Drug Administration drug approvals.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mat Britton is a well-known physiotherapist and local legend who has been part of the Greater Springfield community for many years. He played an integral part in founding the Springfield Runners Group well over a decade ago and through his passion for sport and running, has been able to treat and get people back doing whatever they love to do. In 2014, Mat founded "Trail to Triumph - Tony's Journey" in memory of his dad Tony, who sadly lost his battle to Mesothelioma in March 2014. In October that year TTT was born with the first 250km ultramarathon from Mackay to Moranbah run completed over 2 1/2 gruelling days. It's been run every October and again this year, runners will attempt to complete the 250km Moranbah to Mackay journey from the October 6th - 8th. The event not only is held in memory of Tony Britton but it works to raise awareness and funds to assist in assessment, treatment and research for Mesothelioma and others lung diseases like Silicosis. You can donate to the cause at the below links. As you'll hear in the conversation, Mat has been overwhelmed and truly grateful for the support he has and continues to receive throughout the year through not only the run but also events such as Annual Golf Day, Trivia Night, Brushes and Bubbles and the Virtual Events run. When you attend a function or if you're fortunate enough attend the run up north, you become part of the TTT family which has grown to large numbers, which can be seen by the record group heading up this year. In the conversation with Mat, Steve talks to him about life, how he became a Physio, his reflections on sport, his time in martial arts and plenty of stories in between. It's his love and passion for TTT that truly is a delight within the discussion and his unwavering focus on helping to make a difference to those suffering and experiencing lung diseases that really shines.  Follow Mat Instagram Check out Trail to Triumph Instagram Visit their website Trail To Triumph Donate Here Trail To Triumph Runners   Disclaimer: Important Notice The information provided in Share Podcast is for general informational purposes only. We are not experts in the discussed subjects, and our opinions are personal. While we aim for accuracy, we don't guarantee the completeness or reliability of the information. This podcast should not be considered a substitute for professional advice. Always consult qualified experts for specific advice. We are not liable for any decisions made based on the podcast content. The opinions expressed are those of individuals and not representative of any affiliated entities. The content is protected by copyright and unauthorized use is prohibited.  

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. The theme of the 2023 ASCO Annual Meeting was “Partnering With Patients: The Cornerstone of Cancer Care and Research.” From June 2 to 6 in Chicago, Illinois, and online, cancer researchers and clinicians from around the world gathered to discuss the latest cancer research and how to ensure that all people receive the cancer care they need. In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field presented at the meeting and explain what it means for people with cancer. In today's episode, our guests will discuss new research advances in treating non-small cell lung cancer, small cell lung cancer, and mesothelioma.  Dr. Charu Aggarwal is the Leslye Heisler Associate Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania's Perelman School of Medicine in Philadelphia, Pennsylvania. She is also the 2023 Cancer.Net Associate Editor for Lung Cancer. Dr. Melina Marmarelis is an assistant professor at the University of Pennsylvania, the Medical Director of the Penn Medicine Mesothelioma Program, and the co-director of the Molecular Tumor Board at the University of Pennsylvania. She is also the 2023 Cancer.Net Specialty Editor for Mesothelioma. Dr. Kristin Higgins is a radiation oncologist, Professor and Vice Chair in Clinical Research in the Department of Radiation Oncology at Emory University School of Medicine and medical director of radiation oncology of The Emory Clinic at Winship Cancer Institute's Clifton campus location. She is also a 2023 Cancer.Net Advisory Panelist for Lung Cancer. You can view disclosures for Dr. Aggarwal, Dr. Marmarelis, and Dr. Higgins at Cancer.Net. Dr. Aggarwal: Hello and welcome to this Cancer.Net Research Round Up podcast. Today, we will be talking about the latest research from the Annual Meeting of the American Society of Clinical Oncology from June 2023, and I'm joined today by 2 experts in the field of lung cancer. Before I introduce them, I'd like to introduce myself. I'm Dr. Charu Aggarwal. I'm an associate professor for lung cancer excellence at the University of Pennsylvania's Abramson Cancer Center. I'd now like to introduce Dr. Melina Marmarelis. Dr. Marmarelis: Hi, so happy to be here. I'm Melina Marmarelis. I'm an assistant professor at the University of Pennsylvania and the medical director of the Penn mesothelioma program. Dr. Aggarwal: And Dr. Kristin Higgins. Dr. Higgins: Hi, everyone. I'm Kristin Higgins. I am a thoracic radiation oncologist at Winship Cancer Institute of Emory University. I'm a professor and vice chair for clinical research for radiation oncology. Dr. Aggarwal: Fantastic. So today, we'll talk about relevant research as it applies to practical implications in the clinic for practitioners, but most importantly, patients with lung cancer. I'd like to start off by discussing 2 key studies, and I would love for perspectives from our faculty here. The first study I want to highlight is the ADAURA trial. This is a trial that has already sort of changed practice in most recent years when the study was presented at the Annual Meeting of the American Society of Clinical Oncology in 2020, but we have new updates on this study as of 2023. So, in brief, this was a study that looked at the value of administering an oral pill called osimertinib that is a tyrosine kinase inhibitor against the EGFR, or the epidermal growth factor receptor, in patients with non-small cell lung cancer. We know that non-small cell lung cancer is quite a heterogeneous disease with some subsets of patients having mutations that may render them increasingly sensitive to the effects of these tyrosine kinase inhibitors. In fact, these pills have been used in the metastatic setting for several years based on an improvement in overall survival. What the ADAURA study tried to do was ask the question if this pill would add an incremental advantage after receiving curative-intent surgical resection in those with early-stage lung cancer. So this study enrolled patients with stage IB to IIIA non-small cell lung cancer after surgical resection and focused only on those patients that had sensitizing EGFR mutations with EGFR exon 19 deletion or L858R mutations. Patients could receive chemotherapy after having the surgery and then were basically randomized into 2 groups, one of whom received osimertinib at a dose of 80 milligrams once daily for a total of 3 years. Patients were followed up for recurrence. We already know from the earlier results that patients who received osimertinib had a better chance of delaying the recurrence of disease. However, what we found at the Annual Meeting this year is that the administration of this osimertinib also improved overall survival, which is really what we all look for in the oncology world. If you're administering a therapy, especially for a long duration, we want to be able to see a survival benefit, and that's what we saw. In fact, in patients who received osimertinib, there was a 49% less likelihood of dying from lung cancer compared to those who did not receive osimertinib. This, I think, is practice-affirming. It may not be practice-changing because some of the practitioners started using osimertinib after its FDA approval in December of 2020, but I think it just confirms our practice as it delivers an overall survival advantage in these patients. One thing that's increasingly important is to identify patients who have this mutation, so now we have efforts underway locally as well as nationally to perform molecular genotyping on all patients with lung cancer so that we can adequately and appropriately treat those with early-stage lung cancer following curative resection or following surgery. Melina and Kristin, what are your thoughts? Dr. Marmarelis: Well, I think these results are really important because it did, as you say, affirm kind of what we're already doing, but I think the most convincing part of this for me is the prevention of spread of disease to the brain. This is not comparing osimertinib after surgery versus osimertinib ever, which I think is a difficult part about interpreting this trial. But I think the fact that it prevented disease from going to the brain is really meaningful to everyone, to patients, to the physicians that are caring for them, so I think that's a really important endpoint. Dr. Higgins: I agree with Melina. I think this is really exciting for our patients. It's exciting to have more treatment options for early-stage lung cancer. I think patients that are diagnosed with early-stage lung cancer are highly motivated to do everything they can to improve their likelihood of being cured. So I tend to have a lot of conversations about side effects and toxicities with patients that have questions and are sort of wondering how it will affect their quality of life, and of course, that is an important piece of it because patients that do have curable lung cancer are probably starting off with a better overall quality of life, but I think generally speaking, our patients have tolerated it well. I'm also kind of excited from a radiation oncology point of view. We treat patients with stereotactic body radiation therapy [SBRT] that are medically inoperable. And we have another trial with a cohort looking at osimertinib for those patients that have EGFR mutations, too, and that's ongoing, again, applying the same concept of trying to really use these SBRTs that work really well in the advanced setting, moving them into earlier stages of disease to help us care for more patients. So overall, I think it's really exciting, and I think it's a huge win for the clinical research community. Dr. Aggarwal: Well, that's wonderful. And I think this certainly advances the field as this is the first targeted therapy approved for patients with early-stage non-small cell lung cancer. I should add that AstraZeneca, the company that makes this drug, has provided institutional research funding to my institution, and I also serve as an advisor to them, but I was not involved personally in the research of this clinical trial. I'd like to move on but stay within the field of early-stage lung cancer and talk about another study called the KEYNOTE-671 study, and this is important because it really applies the idea of using immunotherapy before and after surgical resection in patients with early-stage lung cancer. Just to give a little bit of background to our listeners, we now have 3 approvals for the use of immunotherapy in patients with early-stage lung cancer. Two of those are in the adjuvant setting, meaning that if a patient undergoes surgical resection or surgery for early-stage lung cancer, they can receive either atezolizumab or pembrolizumab following that surgery, and that has been shown to improve outcomes in terms of reducing the chances of recurrence. We also have another approval, which is the third approval in early-stage lung cancer, where 3 cycles of chemotherapy and immunotherapy are administered prior to surgery, also called as the neoadjuvant chemo-immunotherapy approach. This drug that has been approved in combination with chemotherapy is nivolumab, and this approval came from a clinical trial called CheckMate 816 that showed both that patients who received this neoadjuvant chemo-immunotherapy approach had a higher proportion of patients who had complete response or pathologic complete response in their tumors at the time of surgery and also showed that the chances of the disease coming back after surgical resection was much lower amongst those that had received this intervention. The current study, the KEYNOTE-671 study, builds upon this concept and adds both a before-surgery intervention as well as an after-surgery intervention. So what this study did was it enrolled patients with early-stage, stage II to IIIB non-small cell lung cancer, and patients in the intervention arm received 4 cycles of chemotherapy in combination with pembrolizumab, underwent surgery, and then received immunotherapy with pembrolizumab for up to 13 cycles. Patients in the control arm received only chemotherapy prior to surgery and then placebo for up to 13 cycles after. This was a large study with about 786 patients randomized, and what we found was that those patients that received the intervention had a much higher likelihood of remaining disease-free or event-free following surgical resection as well as in the early analysis, an improvement in overall survival with about a 27% reduction in the risk of death. So I do think that this is the first study that shows us that use of both neoadjuvant as well as adjuvant. So sort of this perioperative approach of using immunotherapy before and after surgical resection can actually lead to improved outcomes. This is ultimately what we want for our patients, improvement in overall survival, improvement in cure rates, etc. The study has been silent on the use of radiation therapy, although it has gone into details in terms of the kinds of surgery that was done. Kristin, what are your views about this? Dr. Higgins: I think postoperative radiation after resection for non-small cell lung cancer has sort of started to fall out of favor because of the Lung ART trial that was published in Europe, a randomized phase III trial that showed no differences in disease-free survival or overall survival. And that's not to say that there aren't more study questions on ways to give it safer and ways to incorporate radiation in with the chemo-IO approach, and there are some novel ways to do that, and we're going to see some data presented at the World Lung Cancer Conference looking at some of those novel approaches. But standardly, when patients receive neoadjuvant chemo-immunotherapy followed by surgery, we typically would not offer radiation. There are instances, though, when patients have positive margins, for example, and in that situation, it's sort of a discussion on a case-by-case basis. But ideally, we're hoping that most of these patients that go to surgery are able to get a complete resection, and that's really the key component of the decision-making for deciding if patients are eligible for this approach. Dr. Aggarwal: I agree. Melina, any additional thoughts on this trial? Dr. Marmarelis: I think it's an exciting trial for the reasons that you mentioned. I think it does bring up a number of questions about whether both neoadjuvant and adjuvant immunotherapy are needed. I tend to like the idea of having immunotherapy present when the tumor is present before surgery, so I like kind of having that on board, but I think we still don't know which is more important. Dr. Aggarwal: So it certainly raises many more questions, which hopefully will be answered in the future. KEYNOTE-671 trial was conducted by Merck that produces the drug Keytruda, or pembrolizumab. We have received institutional research funding for other trials. I was not personally involved in this clinical trial. I do serve as an advisor for Merck. I think we'll bring you more research from the ASCO Annual Meeting. And I'll turn it over to Dr. Marmarelis to discuss some more exciting research. Dr. Marmarelis: Thanks, Charu. So perhaps it's not surprising that one of the exciting things I picked from ASCO has to do with mesothelioma. And I just want to put into context a little bit about why this trial was important. This is IND227. It was a cooperative group trial done across Canada, France, and Italy, and this was chemotherapy plus or minus pembrolizumab in patients with pleural mesothelioma that did not undergo surgery. So this was their first treatment, and they were not undergoing surgery. And the reason this trial was important is that in the last few years, we had results from CheckMate 743, which was looking at IPI/NIVO, so a combination of immunotherapies versus chemotherapy. And there was an improvement in survival for those that received double immunotherapy, and that improvement was most pronounced in the non-epithelioid population, which is actually a smaller subset of pleural mesotheliomas. And so as we've seen in the lung when we look at immunotherapy versus chemo, it raises the question of whether combination immunotherapy plus chemotherapy would actually be better for all and, in particular, for all histologies in pleural mesothelioma. So this was looking at that concept. It took the standard chemotherapy, carboplatin-pemetrexed or cisplatin-pemetrexed, and then combined it with one immunotherapy, so slightly less than the combo immunotherapy seen in CheckMate 743, and that was pembrolizumab. And what they saw was that there was a small overall survival improvement in the group that got pembrolizumab. Again, that was most pronounced in patients in the non-epithelioid group, so those with sarcomatoid or biphasic histology. And this is really a prelude to several other trials that are coming out in mesothelioma, namely the DREAM3R trial, which is looking at chemotherapy plus or minus durvalumab. That control arm also includes IPI/NIVO, so that will be really important to be able to compare those, and then also the BEAT-meso trial, which is looking at chemotherapy-immunotherapy but also with an anti-VEGF agent, bevacizumab. So I think this was an important trial. It's a little bit of proof of concept, but there's still a lot that we're looking forward to. It's not quite practice-changing in the clinic, although I think it's certainly an option that people are using, but I'm looking for more data going forward. Dr. Aggarwal: It's incredible to see how far we've come in mesothelioma within the last decade. We are introducing immunotherapy. We're introducing novel agents in the first-line setting. Dr. Marmarelis: The other trial that I was interested in was KEYNOTE-789, which is looking also at patients with EGFR mutations and those that had the original osimertinib as their first-line treatment or another tyrosine kinase inhibitor and then had disease progression on that TKI. And this is an area of huge need. We have patients that do really well on targeted therapies, and then they have disease progression, and we're looking for additional targeted options, but we're also looking for effective chemotherapy options. And one of the questions that has risen from this is whether there's a role for immunotherapy. We know that immunotherapy alone in patients with EGFR mutations is not very effective when you look at a broad population, but in combination with chemotherapy, it's possible that it can add some benefit. So this trial looked at those that had EGFR mutations, had disease progression after a targeted therapy, and then it randomized them to chemotherapy plus or minus pembrolizumab, so chemotherapy plus or minus immunotherapy, and interestingly, it had no difference in the progression-free survival or the overall survival. So the 2 arms were really similar in terms of outcomes. There was also no difference in the overall response rates of the amount that the drug actually shrinks the tumor. So it really doesn't look like immunotherapy is adding much to chemotherapy for these patients. I think we still need to look a little bit closer because there are probably some patients with EGFR mutations that could benefit from immunotherapy, but we're really not very good at identifying those. One of the questions that comes up in this space is whether to add anti-VEGF treatment in addition to chemotherapy and immunotherapy. So there are some upcoming trials looking at that. Dr. Aggarwal: I think this was a trial that was actually very important and again, practice-affirming that this idea of continuing chemotherapy without adding immunotherapy, patients are not losing much. In fact, they're not gaining anything by adding immunotherapy as shown in this clinical trial. I think continuing immunotherapy, so continuing osimertinib, may be important in this setting also because we know that osimertinib can cross the blood-brain barrier. It can provide that CNS [central nervous system] protection. Dr. Marmarelis: Yeah, I think that's a great point that the comparison here is not chemotherapy plus osimertinib. It's chemotherapy alone. So I agree that the control arm is not quite what some of us do. I agree. I do the same as you do. I also just want to mention that the KEYNOTE trial and the previous trial about mesothelioma used pembrolizumab, which is made by Merck. We have received institutional funding, and I've served as an advisor as well as received honorarium from Merck.   Dr. Aggarwal: Melina, those were 2 very important studies and certainly, I think, answer some very relevant questions in clinic in the management of patients with EGFR-mutant lung cancer, for example. And then I think we look forward to more practice-changing data in mesothelioma. Kristin, I would love to hear research from ASCO from you. What caught your interest? Dr. Higgins: So I have a special interest in small cell lung cancer. And I think there was one important small cell lung cancer trial that I wanted to review with everyone. It was SWOG S1929. And SWOG is the Southwest Oncology Group, and it's a cooperative group that conducts clinical trials in cancer funded by the National Cancer Institute. And this is a randomized phase II trial of atezolizumab and chemotherapy followed by randomization to continuing the maintenance of atezolizumab with a PARP inhibitor. Now, we know from prior data that PARP inhibition is attractive for small cell lung cancer because PARP is expressed frequently in small cell lung cancer, and there is a biomarker called Schlafen-11 that preclinical data and prior data has shown can predict response to PARP inhibition. And this trial was sort of a proof-of-concept trial, a small, randomized phase II trial testing whether or not that Schlafen-11 biomarker could be used to direct therapy. Now, in this trial, there were 309 patients that were registered. They then had to have their tumor samples sent for central testing for the Schlafen-11 expression. One thing that I think is important to bring up is that in small cell lung cancer, there's this belief that it's really hard to get tissue samples from small cell lung cancer and it's a difficult thing logistically because it's just a lot harder to access these tumors. But interestingly, in this trial, 80% of patients had tumors that were evaluable for the biomarker, and the median time to the test result was only 7 days. So patients were able to get their tumor tested, get it sent out, get results in a rapid manner, and then be randomized based on these results. The primary endpoint for this trial was progression-free survival, and the primary endpoint was met. Progression-free survival was 4.2 months versus 2.8 months. Now, I think many people will say the magnitude of benefit here is not very much, but it's small cell lung cancer, and we don't have a lot of positive trials in this space, and we also don't have many trials that have used a biomarker to direct therapy. So I think for those reasons, it's really exciting to see these results. It was also conducted within a cooperative group with multiple different sites across the United States, and the fact of the matter is that we can do trials like this in small cell lung cancer patients, and I think it will sort of serve as a precedent for future trial design. Now, the overall survival for the trial is still premature. It didn't look that much different with the PARP inhibitor, but that doesn't mean that, again, things could change with more follow-up. And I really like the approach of this trial design, and I'm excited to see biomarker-driven trials in small cell lung cancer. Charu and Melina, what do you guys think about this study? And what do you think about our small cell lung cancer patients and our ability to conduct future trials like this? Dr. Aggarwal: I think this is certainly an advance. As you pointed out, Kristin, it shows us that we can conduct trials in the space. I think it offers a lens into the potential of personalized therapy in small cell lung cancer, which has eluded us for a very long time. The standard of small cell lung cancer has not changed significantly for a very long time, so I think this is very exciting and can't wait to see more things come in the future. Dr. Marmarelis: Yeah, I agree. I think we've always been asking for additional biomarkers, especially in such a difficult disease like small cell. And so this is really exciting to see potential biomarkers and that it was feasible to actually pose that question and study it. So that part's really exciting. Dr. Higgins: Great. And I should also say I was not involved in the study, and I'm not associated with any of the pharmaceutical companies that were involved in the study for S1929. And the final study that we wanted to talk about was the phase III LUNAR study, and this is sort of a different type of trial in the setting of advanced non-small cell lung cancer. It was studying tumor treatment fields with standard of care in metastatic non-small cell lung cancer after progression with platinum-based therapies. And first, I just want to step back and explain what tumor treating fields are. Tumor treating fields are applied to a patient with a transducer that's placed on the skin, and what it does is it applies an electrical field, and that disrupts mitosis when the cancer cells are trying to divide. And the mechanism of cell death is a little bit unclear. There are sort of many mechanisms that are postulated, one of which is immunogenic cell death, but we don't really know, I think, what's happening. But there have been studies that show improved results with tumor treating fields and other diseases. For example, particularly in glioblastoma multiforme, tumor treating fields are used in combination with surgery, radiation, and temozolomide (Temodar). So it's something that's being used in other disease sites, and this is some of the early data that we've seen in metastatic non-small cell lung cancer. And so in this trial, 276 patients were randomized to tumor treating fields plus standard of care or standard of care alone. Now, I should mention that this trial began enrolling patients in 2016, and so the standard of care was very different. After platinum-based therapies, the standard was considered docetaxel. Of course, platinum-based therapy alone for frontline treatment of advanced non-small cell lung cancer is also not the standard of care anymore. And so I think with that in the background, it does make interpretation of these results somewhat difficult, and that's probably the major caveat to this study. But nonetheless, patients were randomized, 276 patients. The primary endpoint of the study was overall survival. They were looking at progression-free survival and overall response rates as secondary endpoints as well as overall survival in patients that received immunotherapy versus just chemotherapy alone. And the trial was positive. Overall survival was improved. The median overall survival was 13.2 months for patients that received tumor treating fields with standard of care versus 9.9 months for standard of care alone. If you look at 3-year survival, it was 18% versus 7%. I think this is a new type of therapy for our patients with non-small cell lung cancer. It is somewhat of a difficult thing to wear the transducer, and you have to wear it for many, many hours. So that is one thing that I think can be difficult for patients that are using this treatment, but nonetheless, it is something new for advanced non-small cell lung cancer. I do know that the technology of tumor treating fields is being studied in other settings for non-small cell lung cancer, for stage III non-small cell lung cancer, for example, and also in the frontline setting. I think this trial kind of speaks to the fact that the landscape of advanced non-small cell lung cancer is changing so rapidly, and when we're studying something novel, we have to make sure that we make these trials feasible for enrollment so that we can get them completed rapidly, and we can get a readout and it doesn't become obsolete based on this shift in the standard of care. So I think it just really kind of drives home that we need to make sure that we're taking that into account with trial design. It's not standard of care changing right now, but it'll be interesting to see how the data evolves over time. Melina, I'm interested to hear your point of view because I know that these can be used in mesothelioma, maybe not that frequently. What is your experience with tumor treating fields, if any? Dr. Marmarelis: Tumor treating fields are approved as a device in pleural mesothelioma in the first-line setting in combination with chemotherapy. They have been used off-label in other settings, but that's the device approval. The trial that looked at tumor treating fields in mesothelioma was a single-arm trial, so there was no control arm, and it was really actually just looking at the safety of the device. So I have not used it personally in mesothelioma, although I know of patients and I know of real-world studies looking at its use, and I think it's potentially an interesting modality of treatment, especially in combination with immunotherapy, given that it really doesn't have a lot of additive toxicity. But I think the question is really, which patients are benefiting from it, and which patients are able to actually wear the vest in the case of mesothelioma? Dr. Higgins: Yeah. Any thoughts, Charu? Dr. Aggarwal: I agree, and I think this is going to be largely driven by patient experience. I think this is going to be quite onerous to wear this, carry the suitcase, so I would be very interested in patient reported outcomes as well as patient experiences and stories, which will really drive our use here. Dr. Higgins: Yeah, that's a great point. I should say that this trial was sponsored by Novocure. My institution does have other Novocure studies underway, and we receive research funding, but I was not involved in the study, and I did not personally receive any research funding. Dr. Aggarwal: Thank you, Kristin. This has been a wonderful review of practice-changing and some promising research that came out of the ASCO Annual Meeting. I hope our listeners enjoyed it, and we'll be sure to update you with the next annual research conference. Thank you, everyone. ASCO: Thank you, Dr. Aggarwal, Dr. Marmarelis, and Dr. Higgins. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

MARS 2 in Spanish--Monday WCLC Highlights In this Spanish-language podcast, Lung Cancer Considered Host Dr. Narjust Florez enlists two colleagues to discuss the MARS 2: A Multicentre Randomized Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma. Guests: Dra. Rosanna Ruiz, Oncologo clínico Institutio nacional de enfermedades neoplásicas, Lima, Peru Dr. Ricardo Terra, Cirujano toracico Professor, the cirugia toracica en la universidad de Sao Paolo, Brazil

Monday at WCLC 2023 features the Presidential Symposium. In this special WCLC 2023 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu talk with Dr. Eric Lim about MARS 2: A Multicentre Randomized Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma. Dr. Paula Ugalde, discussant for MARS 2, provides her unique overview and perspective on research presented today. The hosts also talk with Dr. P.C. Yang about the new results presented in the TALENT study of lung cancer screening in Taiwan. Patient advocate Emi Bossio adds her unique perspective. Additionally, Dr. Pasi Janne summarizes his presidential abstract: Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2) and is joined in a discussion with Emi Bossio, a patient with EGFR lung cancer. Professor Eric Lim is a Consultant Thoracic Surgeon at the Royal Brompton Hospital and Professor of Thoracic Surgery at the National Heart and Lung Institute of Imperial College London. Pan-Chyr Yang, MD, PhD--National Taiwan University College of Medicine and National Taiwan University Hospital, Institute of Biomedical Sciences, Genomics Research Center, Academia Sinica, Taiwan. Paula Ugalde – Dr. Paula Ugalde Figueroa, Thoacic Surgeon, Brigham and Women's Hospital Pasi Jänne is the Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School and the David M. Livingston, MD Chair at Dana-Farber Cancer Institute

This session will review state of the art therapy for peritoneal mesothelioma. The discussion includes cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as well as systemic chemotherapy and immunotherapy. Edward Levine, MD, moderates this podcast and is Professor of Surgery and Chief, Surgical Oncology at Wake Forest University. Trang Nguyen, MD, is an Assistant Professor of Surgery at Indiana University and Sinziana Dumitra, MD, MSc, FRCSC, FSSO, is an Assistant Professor of Surgery at McGill University. 

Rick Greene, MD discusses with Edward A. Levine, MD, long-term survival in patients with malignant peritoneal mesothelioma undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Dr. Levine is the senior author of, “Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center.” Dr. Levine is Professor, Surgical Sciences - Oncology, Chief of Surgical Oncology at Atrium Wake Forest Health, and Section Editor of the Peritoneal Surface Malignancies section of the Annals of Surgical Oncology.  https://link.springer.com/article/10.1245/s10434-022-13061-3

Welcome to episode 184 of the Grow Your Law Firm podcast, hosted by Ken Hardison. In this episode, Ken sits down with Mirena Umizaj from Mirena & Company, to discuss how you can diversify your law firm by growing your firm's inventory.  In the past decade, Mirena successfully deployed a billion dollars to law firms nationwide. She has worked on the largest class-action suits and mass tort settlements in the United States, including the BP Oil spill, IVC Filter, Mesothelioma, Transvaginal Mesh, RoundUp, Hernia Mesh, Boy Scouts, Opioids, Human Trafficking, Route 91-Las Vegas Shooting, Military Earplugs, Talcum Powder, and JUUL litigations.  Mirena is also a Settlement Planning specialist who goes beyond the standard legal conventions, infusing thoughtful and flexible options to clients who receive a recovery. Whether for the Plaintiff or Firm, she improves their bottom line, helping them achieve financial goals of any size and nature. Best of all, her compassion for the plight of the claimant sets her above the rest as she ascertains their well-being through the entire process of the litigation. Mirena's knack for finance and heart to serve provides firms and plaintiffs with holistic, intuitive, and integrated planning to create cutting-edge portfolios. To bring it all full circle, Mirena supplies firms with comprehensive legal concierge services by giving Plaintiffs and Attorneys smooth procedures, detailed reports, and systems of navigating legal planning and funding complexities. By her awareness of market trends and how it affects all aspects of the law she offers a strategic edge in civil justice. She has the wherewithal, drive, discipline, and passion for directing and participating in cases that change our world. Mirena's career began in UNICEF, working as a translator for American troops who assisted Kosovos genocide victims. She subsequently found her way into the US Department of Justice & Immigration, paving the way for her outstanding reputation today. At the young age of 17, Mirena immigrated to the United States from Albania. She earned her degree with honors in International Relations and Communications, graduating from Rollins College in Winter Park, Florida. She fluently speaks three languages, frequently traveling between the US and Europe.     What you'll learn about in this episode: How Mirena got started in the legal business Learn how to grow your inventory Why you should think of your law firm as a business You should stop resisting CFO's How Mirena & Co help law firm owners   Resources:  www.mirenaandco.com https://www.facebook.com/MirenaandCo/ https://www.linkedin.com/company/frameless-consulting-llc/ https://www.instagram.com/mirenaandco/   Additional Resources: https://www.pilmma.org/aiworkshop https://www.pilmma.org/the-mastermind-effect https://www.pilmma.org/resources https://www.pilmma.org/mastermind

Andreas Rimner, MD, Memorial Sloan Kettering Cancer Center, joins us for a conversation about radiation oncology and currently available clinical trials. He discussed various ways patients can benefit from radiation therapy, including an overview of different types of radiation and different modes of treatment. Radiation therapy can be applied alone, or in combination with other treatments such as surgery, chemotherapy, or immunotherapy. Dr. Rimner is a radiation oncologist who specializes in caring for people with cancers of the chest, known as thoracic cancers. These include non-small cell and small cell lung cancers, pleural mesotheliomas, thymomas, lung metastases, sarcomas, and other rare tumors of the chest. He works closely with a highly skilled team of experts from many areas — including surgeons, medical oncologists, radiologists, medical physicists, and radiation therapists — to determine the best treatment options for his patients. HIs team uses the most advanced radiation techniques, including stereotactic body radiation therapy (SBRT) or stereotactic ablative body radiation (SABR), stereotactic radiosurgery (SRS), intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), intensity-modulated pleural radiation therapy (IMPRINT), MR-guided radiation therapy, and proton radiation to precisely target cancers while limiting damage to normal tissues. MesoTV is a program by the Mesothelioma Applied Research Foundation. This program is made possible by our generous sponsors: Maune Raichle Hartley French & Mudd, LLC (MRHFM); Bristol Myers Squibb; Novocure, Merck, The Gori Law Firm, TCR2, AstraZeneca, Early Lucarelli Sweeney & Meisenkothen. Search our previous episodes for topics/speakers of interest to you at www.curemeso.org/mesotv.

In this episode of MesoTV, we are joined by Dr. Ibiayi Dagogo-Jack a thoracic oncologist at the Massachusetts General Hospital and assistant professor of medicine at the Harvard Medical School. She helps us understand the types of immunotherapy treatments currently available to mesothelioma patients, and treatments undergoing clinical trials that might be available in the future. We discuss the ipilimumab/nivolumab (Yervoy/Opdivo) combination, Keytruda (pembrolizumab), and the combination of durvalumab (Imfinzi) with standard chemotherapy that is currently being studied. We also discuss targeted therapies. Dr. Dagogo-Jack explains in a very approachable way the theory behind immunotherapy in general, as well as why certain immunotherapies might be better choices for certain patients. Dr. Ibiayi Dagogo-Jack received her bachelor's degree from Vanderbilt University and her medical degree from the University of Chicago Pritzker School of Medicine. She trained in internal medicine at Brigham and Women's Hospital. Following residency, she completed hematology/oncology fellowship in the combined Massachusetts General Hospital/Dana Farber Cancer Institute program. She is an Assistant Professor of Medicine at Harvard Medical School and a medical oncologist at Massachusetts General Hospital where she specializes in thoracic cancers. She conducts clinical/translational research focused on understanding mechanisms underlying resistance to cancer therapeutics and clinical trials designed to evaluate novel combinations in lung cancer and mesothelioma.

New Series: Culture Change- Gun laws, registration, training and insurance will make us safer. But how do we change the gun culture in our country? This week on Radio GAG from The UK, a week without gun violence. Ti Cersley discusses national safety, government corruption and activism with friend Julie Roberts who raised awareness of Mesothelioma in Scotland. In Memoriam Christine Michael. Sean Stefanic reports the Gun Violence Prevention news and we prepare for St Pat's For All Parade, Sunday March 5th in Queens.

CardioNerds Cofounder Dr. Amit Goyal is joined by an esteemed group of UCLA cardiology fellows – Dr. Patrick Zakka (CardioNerds Academy Chief), Dr. Negeen Shehandeh (Chief Fellow), and Dr. Adrian Castillo – to discuss a case of primary cardiac angiosarcoma. An expert commentary is provided by Dr. Eric Yang, beloved educator, associate clinical professor of medicine, assistant fellowship program director, and founder of the Cardio-Oncology program at UCLA.   Case synopsis: A female in her 40s presents to the ED for fatigue that had been ongoing for approximately 1 month. She also developed night sweats and diffuse joint pains, for which she has been taking NSAIDs. She was seen by her PCP and after bloodwork was done, was told she had iron deficiency so was on iron replacement therapy. Vital signs were within normal limits. She was in no acute distress. Her pulmonary and cardiac exams were unremarkable. Her lab studies showed a Hb of 6.6 (MCV 59) and platelet count of 686k. CXR was without significant abnormality, and EKG showed normal sinus rhythm. She was admitted to medicine and received IV iron (had not consented to receiving RBC transfusion). GI was consulted for anemia work-up. Meanwhile, she developed a new-onset atrial fibrillation with rapid ventricular response seen on telemetry, for which Cardiology was consulted. A TTE was ordered in part of her evaluation, and surprisingly noted a moderate pericardial effusion circumferential to the heart. Within the pericardial space, posterior to the heart and abutting the RA/RV was a large mass measuring approximately 5.5x5.9 cm. After further imaging work-up with CMR and PET-CT, the mass was surgically resected, and patient established care with outpatient oncology for chemotherapy.  CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Media - primary cardiac angiosarcoma Episode Schematics & Teaching Pearls – primary cardiac angiosarcoma The pericardium is composed of an outer fibrous sac, and an inner serous sac with visceral and parietal layers.   Pericardial masses can be primary (benign or malignant) or metastatic. There are other miscellaneous pericardial masses.  Imaging modalities for the pericardium include echocardiography, cardiac CT and cardiac MRI. There is also role for PET-CT in pericardial imaging for further characterization of pericardial masses.   Cardiac angiosarcomas are extremely rare but are the most common cardiac primary malignant tumors.  Evidence-based management if lacking because of paucity of clinical data given the rarity of cardiac angiosarcomas. Surgery is the mainstay of therapy. Radiotherapy and chemotherapy are often used as well.  Notes – primary cardiac angiosarcoma Pericardial Anatomy  The pericardium is a fibroelastic sac composed of two layers.   Outer layer: fibrous pericardium (